Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 155 clinical trials
Dupilumab Asthma Sleep Study

Primary Objective: To assess the effect of dupilumab on sleep Secondary Objectives: To evaluate the effect of dupilumab on additional patient reported sleep outcomes To evaluate the effect of dupilumab on objective sleep assessment To evaluate the effect of dupilumab on asthma symptoms To evaluate the effect of dupilumab on …

eosinophil count
forced expiratory volume
polysomnography
pulmonary function test
dupilumab
  • 0 views
  • 19 Feb, 2024
  • 10 locations
KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated Nonsquamous NSCLC

This is a Phase 2, randomized, multicenter, double-blind study of the glutaminase inhibitor telaglenastat with standard-of-care pembrolizumab and chemotherapy versus placebo with standard-of-care pembrolizumab and chemotherapy for first line treatment of metastatic disease in patients with KEAP1/NRF2-mutated, stage IV, nonsquamous, non-small cell lung cancer (NSCLC). The study primary endpoints are …

adjuvant
liquid biopsy
systemic therapy
proto-oncogene tyrosine-protein kinase ros
stage iv non-small cell lung cancer
  • 0 views
  • 19 Feb, 2024
Bioequivalence and the Tolerability and Antitumor Activity of Selinexor Combination Treatment

This is a Phase 1, two-part, two-arm, open-label study in patients with NSCLC who have had 1 or 2 prior lines of treatment, with 1 line containing a CPI, or patients with CRC who have had 2 prior lines of treatment (oxaliplatin- and irinotecan-based) and no prior immunotherapy. The study …

kras
fluorouracil
folfiri regimen
metastatic nsclc
solid tumor
  • 0 views
  • 19 Feb, 2024
Smartphone Application for Initiation of Protective Ventilation. Clinical Impact of Instrumental Dead Space Reduction

Clinical evaluation of a new educative tools (Smartphone application) based on impact of instrumental dead space reduction after initiation of protective ventilation during mechanical ventilation.

mechanical ventilation
vasopressor
assist control
  • 0 views
  • 19 Feb, 2024
Clinical Surveillance vs. Anticoagulation for Low-risk Patients With Isolated Subsegmental Pulmonary Embolism

Whether isolated SSPE represents "true" PE, a clinically more benign form of PE, a physiologic lung clearing process, or a false positive result (artifact) is currently unclear and hence, whether patients with isolated SSPE benefit from anticoagulant treatment is uncertain.

deep vein thrombosis
embolism
pulmonary embolism
thromboembolism
lung diseases
  • 0 views
  • 19 Feb, 2024
Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity

Participants are assigned to one of 8 cohorts based on their primary tumour type: breast, lung, gastrointestinal (GI), primary unknown, genitourinary (GU), sarcoma, gynecological, and 'other' cancer types. Participants in all cohorts will receive the same dose of atezolizumab (1200 mg every 3 weeks).

platelet count
serum bilirubin
absolute neutrophil count
g-csf
bone metastases
  • 0 views
  • 19 Feb, 2024
A Study to Evaluate the Safety Pharmacokinetics and Activity of GDC-6036 in Patients With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation

This is a Phase I dose-escalation and dose-expansion study that will evaluate the safety, pharmacokinetics (PK), and preliminary activity of GDC-6036 in patients with advanced or metastatic solid tumors with a KRAS G12C mutation.

kras
metastatic malignant solid tumor
ki-ras
kras g12c mutation
solid tumour
  • 0 views
  • 19 Feb, 2024
First-in-Human Dose Escalation Trial of ATRC-101 in Adults With Advanced Solid Malignancies

ATRC-101-A01 is a first-in-human, Phase 1b, open-label trial to characterize the safety, tolerability, pharmacokinetics (PK), and biological activity of escalating doses of ATRC-101, an engineered, fully human immunoglobulin G, subclass 1 (IgG1) antibody derived from a naturally-occurring human antibody.

measurable disease
cancer
melanoma
non-small cell lung cancer
cancer therapy
  • 0 views
  • 19 Feb, 2024
Brief Title: Study of BGB-10188 as Monotherapy and in Combination With Zanubrutinib and Tislelizumab

The purpose of this study is to determine the maximum tolerated dose (MTD), recommended Phase 2 dose(RP2D),safety & tolerability of BGB-10188: as monotherapy in participants with mature B-cell malignancies; oin combination with zanubrutinib in participants with relapse/refractory follicular lymphoma (R/R FL), mantle cell lymphoma (MCL) or diffuse large B-cell lymphoma …

large b-cell lymphoma
tislelizumab
transitional cell carcinoma
lymphoma
endometrial carcinoma
  • 0 views
  • 19 Feb, 2024
A Study of SGN-B6A in Advanced Solid Tumors

This trial will look at a drug called SGN-B6A to find out whether it is safe for people who have solid tumors. It will study SGN-B6A to find out what its side effects are. A side effect is anything the drug does besides treating cancer. It will also study whether …

cervical cancer
gastric cancer
squamous cell carcinoma of the head and neck
squamous cell carcinoma of head and neck
bladder cancer
  • 0 views
  • 19 Feb, 2024